plecanatide (Trulance)
Jump to navigation
Jump to search
Indications
- adults with chronic idiopathic constipation
Contraindications
- persons < 18 years of age (children & adolecents)
Dosage
Mechanism of action
- guanylate cyclase-C agonist
- stimulates secretion of intestinal fluid
More general terms
References
- ↑ FDA News Release. Jan 19, 2017 FDA approves Trulance for Chronic Idiopathic Constipation. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm537725.htm
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ DeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2017 Nov;10(11):837-851. Epub 2017 Oct 25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29147135 Free PMC Article
- ↑ TRULANCE (plecanatide) prescribing information http://content.stockpr.com/synergypharma/files/pages/synergypharma/db/147/description/03+Plecanatide+label_clean_2017-01-19.pdf